Trending Stocks : Bharti Airtel, L&T, ETC..

The Friday equity market closed higher thanks to new foreign fund inflows and buying by index heavyweight Reliance Industries. The Nifty increased 49.85 points to 17,786.80, and the Sensex increased 203.01 points, or 0.34 percent, to settle at 59,959.85.

Lupin: The Nagpur Unit-2 injectable production facility of Lupin was inspected by the US FDA. A Pre-Approval Inspection (PAI) of the injectable facility was conducted. With the issuance of a Form-483 with five observations, the inspection came to an end.

NTPC: Due to rising expenses, the state-run power company NTPC had a more than 7% decline in its consolidated net profit for the second quarter, coming in at Rs 3,417.67 crore. The company’s combined net profit for the quarter was Rs 3,690.95 crore.

ICRA, a credit rating agency, has reiterated Hindustan Copper’s Long-Term Rating of AA+ and Short-Term Rating of A1+. The long-term rating’s prognosis is steady.

The top 10 Sensex gainers, up to 4.95 percent, including Maruti, Reliance Industries, NTPC, Power Grid, Mahindra & Mahindra, Bajaj Finserv, Titan, and Kotak Mahindra Bank.

Here are some stocks that are likely to continue receiving news coverage today.

Income today: Among the companies releasing their September quarter profits today are 3i Infotech, Asahi India Glass, Bharti Airtel, Castrol India, LT Foods, Larsen & Toubro, Saregama Industries, Swaraj Engines, and Tata Steel.

Vedanta: Due to rising expenses, the mining company Vedanta recorded a consolidated net profit decline of 60.8% in Q2 to Rs 1,808 crore. In the same time a year prior, the company reported a combined net profit of Rs. 4,615 crore.

Maruti Suzuki: Thanks to record sales, the automaker’s consolidated net profit increased by more than four times to Rs 2,112.5 crore in the second quarter that ended September 30, 2022.

Blue Dart: The business recorded total revenues of Rs 1,325 crore, up 17.95% from the same period last year. Net profit margin decreased from 9.18% in Q1FY23 to 7.07% in Q2FY23, which is lower than both 8.06% and 8.06% in Q1FY22.

Zydus Lifesciences: The US Food and Drug Administration (USFDA) has given the business the go-ahead to market Acetaminophen Injection, 1,000 mg/100mL (10 mg/mL) single-dose vials (USRLD: Ofirmev)
The US FDA has finished a PreApproval Inspection (PAI) at Laurus Labs’ production facility in Unit-5, Parawada, Visakhapatnam, Andhra Pradesh, and has issued a Form 483 with one observation.

Blue Dart: The business recorded total revenues of Rs 1,325 crore, up 17.95% from the same period last year. Net profit margin decreased from 9.18% in Q1FY23 to 7.07% in Q2FY23, which is lower than both 8.06% and 8.06% in Q1FY22.

Zydus Lifesciences: The US Food and Drug Administration (USFDA) has given the business the go-ahead to market Acetaminophen Injection, 1,000 mg/100mL (10 mg/mL) single-dose vials (USRLD: Ofirmev)
The US FDA has finished a PreApproval Inspection (PAI) at Laurus Labs’ production facility in Unit-5, Parawada, Visakhapatnam, Andhra Pradesh, and has issued a Form 483 with one observation.